RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Recruiting

Early Phase 1

RP1RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Sponsor:

Yana Najjar

Code:

NCT06216938

Conditions

Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Vusolimogene oderparepvec (RP1)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Yana Najjar on 2025-04-10.